Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 versus investigator's choice in previously treated advanced colorectal cancer
CTR20234257Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in colorectal cancer (CRC), sponsored by Hengrui Therapeutics. Started Mar 2024; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20234257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234257.